Anaplastic carcinoma showing rhabdoid features combined with ovarian mucinous borderline cystadenoma: a case report and literature review

• Published in: Journal of international medical research Vol. 49; no. 5; p. 3000605211013159
• Main Authors: Sun, Tingting, Tian, Liming, Guo, Yunyun, Zheng, Yu, Ouyang, Linglong, Zhang, Xianbin, Lai, Yingrong, Yang, Guofen
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.05.2021; Sage Publications Ltd; SAGE Publishing
• Subjects: Case Report; Case reports; Cysts; Medical prognosis; Ovarian cancer; Ovaries; Anaplastic carcinoma; ovarian neoplasm; immunohistochemistry; mural nodule; chemotherapy; ovarian mucinous borderline cystadenoma
• ISSN: 0300-0605; 1473-2300
• DOI: 10.1177/03000605211013159

Anaplastic carcinoma in an ovarian tumor (ACOT) is rare. There have been a few controversial cases illustrating the clinical characteristics and prognostic factors of ACOT, which are not well known. A 60-year-old Chinese woman presented with a large pelvic tumor. A transvaginal ultrasound examination showed a large single ovarian cystic tumor with mural nodules and ascites. A gross ovarian mass with a size of approximately 20 × 10×15 cm3 was found. The content of the ovarian cyst was light yellow and chocolate-like, and a large grayish mural nodule of approximately 10 cm was found on the cyst wall. Histological diagnosis of ovarian mucinous borderline cystadenoma with a mural nodule of anaplastic carcinoma showing rhabdoid features and International Federation of Gynecology and Obstetrics (FIGO) stage IIIa was made. Fifteen months after surgery, the patient had received six courses of paclitaxel and carboplatin. She is still alive without any recurrence of the tumor. Findings from the present case suggest that patients with ACOT and FIGO stage IIIa would benefit from surgery and chemotherapy of paclitaxel and carboplatin. We also review the clinical features and survival rate of patients with ACOT using the Surveillance, Epidemiology, and End Result database, and summarize previously reported treatments.